Author of

• 14704

  +

  P2.11 - Poster Session/ Palliative and Supportive Care (ID 230)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Palliative and Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14706

    +

    P2.11-002 - Identifying Relationship between Symptom Burden and Overall Survival in Patients with Advanced Nonsmall Cell Lung Cancer: A Prospective Study (ID 2883)

    09:30 - 09:30  |  Author(s): Ü. Yılmaz
    • Abstract

    Background:
    Prognostic factors in nonsmall cell lung carsinoma (NSCLC) has been described in many studies in medical literature. It is unclear the relationship between overall survival and symptom burden. The aim of our study is defining the prognostic factors in advanced NSCLC and to describe relationship between symptoms and overall survival.
    
    Methods:
    In this study, the patients newly diagnosed stage 3b and 4 with NSCLC and Eastern Cooperative Oncology Group Performans Status (ECOG PS) of 0 to 2, from August 2011 to May 2013 in Ataturk Chest Diseases and Chest Surgery Education and Training Hospital were included. We obtained the demographic, diseases related and laboratory data for all patients. Symptoms were analyzed with The Edmonton Symptom Assessment Scale (ESAS) before and after chemotherapy. The study was designed prospectively and the patients were followed up to 826 days. Cox model proportional risk analysis was performed at the end of the the followed-up period to assess the beginning symptoms, symptoms differences after chemotheraphy and the relationship between the general characteristics and the survival.
    
    Results:
    We conducted a multivariate analysis and it is found that as one of the general characteristics; the stage of the diseases (p= 0,004 HR: 2,373 95% CI: 1,317-4,274) and the histopathologic subtypes (p=0,006 HR: 2,311 95% CI:1,271-4,202) were prognostically significant. The patients with fatigue as the beginning symptoms (p=0,001 HR:2,389 %95 % CI: 1,460-3,908) and the sadness score 4 and over (p= 0,032 HR:2,311 95% CI: 1,271-4,202) had lower survival, it is also found that patients with cough intensity increasing after chemotheraphy (p=0,006 HR: 1,933 95% CI: 1,128-3,314) had lower survival and high mortality risk as well in multivariate analysis.
    
    Conclusion:
    During the treatment process, together with performance scores of patients with symptom score monitoring will be meaningful. Further prospective studies including a larger group of patients are required in order to describe better the relationship between the symptoms and the prognosis.